Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 5, 2026 20:14 UTC |
Cobo MarcPrincipal Accounting Officer
|
Tax withholdingCommon Stock | 126 | $3.94 | $496.44 |
DisclosureSEC source: 0001193125-26-414135 · ownership.xml · nonDerivative · entry 1 Cobo Marc · CIK 0001816654 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,015 F1 · shares: Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| October 01, 2026 Filed Oct 5, 2026 20:13 UTC |
Elmelech IdanCOO & Principal Financial Ofcr
|
Tax withholdingCommon Stock | 343 | $3.94 | $1,351.42 |
DisclosureSEC source: 0001193125-26-414131 · ownership.xml · nonDerivative · entry 1 Elmelech Idan · CIK 0002058437 · COO & Principal Financial Ofcr 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,152 F1 · shares: Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| October 01, 2026 Filed Oct 5, 2026 20:12 UTC |
Beltran PedroDirector · President and CEO
|
Tax withholdingCommon Stock | 1,047 | $3.94 | $4,125.18 |
DisclosureSEC source: 0001193125-26-414127 · ownership.xml · nonDerivative · entry 1 Beltran Pedro · CIK 0002058152 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,529 F1 · shares: Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| October 01, 2026 Filed Oct 5, 2026 20:11 UTC |
Ben YongChief Med & Dev Officer
|
Tax withholdingCommon Stock | 1,047 | $3.94 | $4,125.18 |
DisclosureSEC source: 0001193125-26-414123 · ownership.xml · nonDerivative · entry 1 Ben Yong · CIK 0001967669 · Chief Med & Dev Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,529 F1 · shares: Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| September 10, 2026 Filed Sep 14, 2026 20:24 UTC |
Cobo MarcPrincipal Accounting Officer
|
GrantStock Option (Right to Buy) · Derivative | 43,700 | $0.00 Strike: $5.52 | $0.00 |
DisclosureSEC source: 0001193125-26-390624 · ownership.xml · derivative · entry 3 Cobo Marc · CIK 0001816654 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,700 Underlying: Common Stock · 43,700 shares Expires 2036-09-09 F3 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of April 21, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| September 10, 2026 Filed Sep 14, 2026 20:24 UTC |
Cobo MarcPrincipal Accounting Officer
|
Tax withholdingCommon Stock | 203 | $5.52 | $1,120.56 |
DisclosureSEC source: 0001193125-26-390624 · ownership.xml · nonDerivative · entry 2 Cobo Marc · CIK 0001816654 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,141 F2 · shares: Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| September 10, 2026 Filed Sep 14, 2026 20:24 UTC |
Cobo MarcPrincipal Accounting Officer
|
GrantCommon Stock | 9,038 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-390624 · ownership.xml · nonDerivative · entry 1 Cobo Marc · CIK 0001816654 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,344 F1 · shares: Represents a grant of restricted stock units ("RSUs"), each representing a contingent right to receive one share of the Issuer's Common Stock. The RSUs vest in 16 equal quarterly installments over a period of four years from April 21, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. The RSUs will be settled in shares of Common Stock upon vesting. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 22:00 UTC |
Ben YongChief Med & Dev Officer
|
Tax withholdingCommon Stock | 1,047 | $7.80 | $8,166.60 |
DisclosureSEC source: 0001193125-26-296502 · ownership.xml · nonDerivative · entry 1 Ben Yong · CIK 0001967669 · Chief Med & Dev Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,576 F1 · shares: Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 22:00 UTC |
Cobo MarcPrincipal Accounting Officer
|
Tax withholdingCommon Stock | 125 | $7.80 | $975.00 |
DisclosureSEC source: 0001193125-26-296504 · ownership.xml · nonDerivative · entry 1 Cobo Marc · CIK 0001816654 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,306 F1 · shares: Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 22:00 UTC |
Beltran PedroDirector · President and CEO
|
Tax withholdingCommon Stock | 1,047 | $7.80 | $8,166.60 |
DisclosureSEC source: 0001193125-26-296501 · ownership.xml · nonDerivative · entry 1 Beltran Pedro · CIK 0002058152 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,576 F1 · shares: Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 22:00 UTC |
Elmelech IdanCOO & Principal Financial Ofcr
|
Tax withholdingCommon Stock | 343 | $7.80 | $2,675.40 |
DisclosureSEC source: 0001193125-26-296503 · ownership.xml · nonDerivative · entry 1 Elmelech Idan · CIK 0002058437 · COO & Principal Financial Ofcr 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,495 F1 · shares: Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 20:34 UTC |
Chen BihuaDirector · 10% owner
|
OtherCommon Stock | 130,865 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-075538 · ownership.xml · nonDerivative · entry 4 Chen Bihua · CIK 0001599214 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Via Master Fund Disclosed balance after: 6,083,221 F4 · kind: Cormorant Global Healthcare Master Fund, LP ("Master Fund"), which is an investment vehicle managed by CAM, is a member of the Sponsor and received such shares in a pro rata distribution by the Sponsor for no consideration. F6 · ownership.nature: CAM serves as the investment manager to Fund III, Cormorant Private Healthcare Fund IV, LP ("Fund IV"), Fund V, and Master Fund (collectively, the "Cormorant Funds"). Cormorant Private Healthcare GP III, LLC ("GP III") is the general partner of Fund III; Cormorant Private Healthcare GP IV, LLC ("GP IV") is the general partner of Fund IV; Cormorant Private Healthcare GP V, LLC ("GP V") is the general partner of Fund V; and Cormorant Global Healthcare GP, LLC ("Global GP") is the general partner of the Master Fund. Bihua Chen serves as the managing member of GP III, GP IV, GP V, and Global GP, and as the general partner of CAM. Accordingly, Ms. Chen has voting and investment discretion with respect to the shares held by each of the Cormorant Funds and CAM. Ms. Chen disclaims any beneficial ownership of the securities held by each of the Cormorant Funds other than to the extent of any pecuniary interest she may have therein, directly or indirectly. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 20:34 UTC |
Chen BihuaDirector · 10% owner
|
OtherCommon Stock | 1,704,862 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-075538 · ownership.xml · nonDerivative · entry 3 Chen Bihua · CIK 0001599214 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Via Fund V Disclosed balance after: 5,010,332 F3 · kind: Cormorant Private Healthcare Fund V, LP ("Fund V"), which is an investment vehicle managed by CAM, is a member of the Sponsor and received such shares in a pro rata distribution by the Sponsor for no consideration. F6 · ownership.nature: CAM serves as the investment manager to Fund III, Cormorant Private Healthcare Fund IV, LP ("Fund IV"), Fund V, and Master Fund (collectively, the "Cormorant Funds"). Cormorant Private Healthcare GP III, LLC ("GP III") is the general partner of Fund III; Cormorant Private Healthcare GP IV, LLC ("GP IV") is the general partner of Fund IV; Cormorant Private Healthcare GP V, LLC ("GP V") is the general partner of Fund V; and Cormorant Global Healthcare GP, LLC ("Global GP") is the general partner of the Master Fund. Bihua Chen serves as the managing member of GP III, GP IV, GP V, and Global GP, and as the general partner of CAM. Accordingly, Ms. Chen has voting and investment discretion with respect to the shares held by each of the Cormorant Funds and CAM. Ms. Chen disclaims any beneficial ownership of the securities held by each of the Cormorant Funds other than to the extent of any pecuniary interest she may have therein, directly or indirectly. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 20:34 UTC |
Chen BihuaDirector · 10% owner
|
OtherCommon Stock | 2,692,459 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-075538 · ownership.xml · nonDerivative · entry 2 Chen Bihua · CIK 0001599214 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Via Fund III Disclosed balance after: 4,879,995 F2 · kind: Cormorant Private Healthcare Fund III, LP ("Fund III"), which is an investment vehicle managed by Cormorant Asset Management, LP ("CAM"), is a member of the Sponsor and received such shares in a pro rata distribution by the Sponsor for no consideration. F6 · ownership.nature: CAM serves as the investment manager to Fund III, Cormorant Private Healthcare Fund IV, LP ("Fund IV"), Fund V, and Master Fund (collectively, the "Cormorant Funds"). Cormorant Private Healthcare GP III, LLC ("GP III") is the general partner of Fund III; Cormorant Private Healthcare GP IV, LLC ("GP IV") is the general partner of Fund IV; Cormorant Private Healthcare GP V, LLC ("GP V") is the general partner of Fund V; and Cormorant Global Healthcare GP, LLC ("Global GP") is the general partner of the Master Fund. Bihua Chen serves as the managing member of GP III, GP IV, GP V, and Global GP, and as the general partner of CAM. Accordingly, Ms. Chen has voting and investment discretion with respect to the shares held by each of the Cormorant Funds and CAM. Ms. Chen disclaims any beneficial ownership of the securities held by each of the Cormorant Funds other than to the extent of any pecuniary interest she may have therein, directly or indirectly. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 20:34 UTC |
Chen BihuaDirector · 10% owner
|
OtherCommon Stock | 4,528,186 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-075538 · ownership.xml · nonDerivative · entry 1 Chen Bihua · CIK 0001599214 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Via Helix Holdings II LLC Disclosed balance after: 0 F1 · kind: Represents a pro rata distribution to the members of Helix Holdings II LLC (the "Sponsor") for no consideration. F5 · ownership.nature: Sponsor is the record holder of the securities reported herein. Fund III, Fund V, and Master Fund are the members of Sponsor. Bihua Chen is the manager of Sponsor and has voting and investment discretion with respect to the shares held of record by Sponsor. Each of Fund III, Fund V, Master Fund and Ms. Chen disclaims any beneficial ownership of the securities held by Sponsor other than to the extent of any pecuniary interest she or it may have therein, directly or indirectly. Read SEC document |
| June 16, 2026 Filed Jun 18, 2026 20:59 UTC |
Tipirneni Praveen P.Director
|
GrantStock Option (Right to Buy) · Derivative | 31,675 | $0.00 Strike: $7.73 | $0.00 |
DisclosureSEC source: 0001193125-26-276050 · ownership.xml · derivative · entry 1 Tipirneni Praveen P. · CIK 0001779978 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,675 Underlying: Common Stock · 31,675 shares Expires 2036-06-15 F1 · derivative.exercise_date: The shares underlying the stock option vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting of Stockholders of the Issuer following the date of grant, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. Read SEC document |
| June 16, 2026 Filed Jun 18, 2026 20:58 UTC |
MCCORMICK FRANKDirector
|
GrantStock Option (Right to Buy) · Derivative | 31,675 | $0.00 Strike: $7.73 | $0.00 |
DisclosureSEC source: 0001193125-26-276048 · ownership.xml · derivative · entry 1 MCCORMICK FRANK · CIK 0001257809 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,675 Underlying: Common Stock · 31,675 shares Expires 2036-06-15 F1 · derivative.exercise_date: The shares underlying the stock option vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting of Stockholders of the Issuer following the date of grant, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. Read SEC document |
| June 16, 2026 Filed Jun 18, 2026 20:57 UTC |
Lebowitz Peter FDirector
|
GrantStock Option (Right to Buy) · Derivative | 7,289 | $0.00 Strike: $7.73 | $0.00 |
DisclosureSEC source: 0001193125-26-276046 · ownership.xml · derivative · entry 1 Lebowitz Peter F · CIK 0002121402 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,289 Underlying: Common Stock · 7,289 shares Expires 2036-06-15 F1 · derivative.exercise_date: The shares underlying the stock option vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting of Stockholders of the Issuer following the date of grant, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. Read SEC document |
| June 16, 2026 Filed Jun 18, 2026 20:55 UTC |
Chen BihuaDirector · 10% owner
|
GrantStock Option (Right to Buy) · Derivative | 31,675 | $0.00 Strike: $7.73 | $0.00 |
DisclosureSEC source: 0001193125-26-276041 · ownership.xml · derivative · entry 1 Chen Bihua · CIK 0001599214 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,675 Underlying: Common Stock · 31,675 shares Expires 2036-06-15 F1 · derivative.exercise_date: The shares underlying the stock option vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting of Stockholders of the Issuer following the date of grant, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. Read SEC document |
| June 16, 2026 Filed Jun 18, 2026 20:56 UTC |
Kelleher Raymond J.Director
|
GrantStock Option (Right to Buy) · Derivative | 31,675 | $0.00 Strike: $7.73 | $0.00 |
DisclosureSEC source: 0001193125-26-276043 · ownership.xml · derivative · entry 1 Kelleher Raymond J. · CIK 0002058193 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,675 Underlying: Common Stock · 31,675 shares Expires 2036-06-15 F1 · derivative.exercise_date: The shares underlying the stock option vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting of Stockholders of the Issuer following the date of grant, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. Read SEC document |
| June 16, 2026 Filed Jun 18, 2026 20:54 UTC |
Bauer JakeDirector
|
GrantStock Option (Right to Buy) · Derivative | 31,675 | $0.00 Strike: $7.73 | $0.00 |
DisclosureSEC source: 0001193125-26-276035 · ownership.xml · derivative · entry 1 Bauer Jake · CIK 0001654909 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,675 Underlying: Common Stock · 31,675 shares Expires 2036-06-15 F1 · derivative.exercise_date: The shares underlying the stock option vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting of Stockholders of the Issuer following the date of grant, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. Read SEC document |
| June 16, 2026 Filed Jun 18, 2026 20:53 UTC |
Kumar NeilDirector
|
GrantStock Option (Right to Buy) · Derivative | 31,675 | $0.00 Strike: $7.73 | $0.00 |
DisclosureSEC source: 0001193125-26-276033 · ownership.xml · derivative · entry 1 Kumar Neil · CIK 0001742485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,675 Underlying: Common Stock · 31,675 shares Expires 2036-06-15 F1 · derivative.exercise_date: The shares underlying the stock option vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting of Stockholders of the Issuer following the date of grant, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. Read SEC document |
| May 10, 2026 Filed May 12, 2026 20:12 UTC |
Elmelech IdanCOO & Principal Financial Ofcr
|
GrantStock Option (Right to Buy) · Derivative | 758,222 | $0.00 Strike: $7.66 | $0.00 |
DisclosureSEC source: 0001193125-26-219447 · ownership.xml · derivative · entry 1 Elmelech Idan · CIK 0002058437 · COO & Principal Financial Ofcr 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 758,222 Underlying: Common Stock · 758,222 shares Expires 2036-05-09 F1 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of April 20, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| May 10, 2026 Filed May 12, 2026 20:11 UTC |
Beltran PedroDirector · President and CEO
|
GrantStock Option (Right to Buy) · Derivative | 1,103,837 | $0.00 Strike: $7.66 | $0.00 |
DisclosureSEC source: 0001193125-26-219439 · ownership.xml · derivative · entry 1 Beltran Pedro · CIK 0002058152 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,103,837 Underlying: Common Stock · 1,103,837 shares Expires 2036-05-09 F1 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of April 20, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| April 01, 2026 Filed May 5, 2026 23:05 UTC |
Ben YongChief Med & Dev Officer
|
Tax withholdingCommon Stock | 1,047 | $9.03 | $9,454.41 |
DisclosureSEC source: 0001193125-26-207041 · ownership.xml · nonDerivative · entry 1 Ben Yong · CIK 0001967669 · Chief Med & Dev Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,623 F1 · shares: Represents shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| April 01, 2026 Filed May 5, 2026 23:01 UTC |
Mehra UneekFormer Officer
|
Tax withholdingCommon Stock | 524 | $9.03 | $4,731.72 |
DisclosureSEC source: 0001193125-26-207031 · ownership.xml · nonDerivative · entry 1 Mehra Uneek · CIK 0001881504 · Former Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,806 F1 · shares: Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| April 01, 2026 Filed May 5, 2026 23:03 UTC |
Beltran PedroDirector · President and CEO
|
Tax withholdingCommon Stock | 1,047 | $9.03 | $9,454.41 |
DisclosureSEC source: 0001193125-26-207035 · ownership.xml · nonDerivative · entry 1 Beltran Pedro · CIK 0002058152 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,623 F1 · shares: Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| March 24, 2026 Filed Mar 26, 2026 21:14 UTC |
Lebowitz Peter FDirector
|
GrantStock Option (Right to Buy) · Derivative | 63,350 | $0.00 Strike: $8.72 | $0.00 |
DisclosureSEC source: 0001193125-26-126602 · ownership.xml · derivative · entry 1 Lebowitz Peter F · CIK 0002121402 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,350 Underlying: Common Stock · 63,350 shares Expires 2036-03-23 F1 · derivative.exercise_date: 1/36th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of March 24, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:56 UTC |
Ben YongChief Med & Dev Officer
|
GrantStock Option (Right to Buy) · Derivative | 210,000 | $0.00 Strike: $10.19 | $0.00 |
DisclosureSEC source: 0001193125-26-104369 · ownership.xml · derivative · entry 2 Ben Yong · CIK 0001967669 · Chief Med & Dev Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 210,000 Underlying: Common Stock · 210,000 shares Expires 2036-03-09 F2 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:56 UTC |
Ben YongChief Med & Dev Officer
|
GrantCommon Stock | 46,670 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-104369 · ownership.xml · nonDerivative · entry 1 Ben Yong · CIK 0001967669 · Chief Med & Dev Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,670 F1 · shares: Represents a grant of restricted stock units ("RSUs"), each representing a contingent right to receive one share of the Issuer's Common Stock. The RSUs vest in 16 equal quarterly installments over a period of four years from January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. The RSUs will be settled in shares of Common Stock upon vesting. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:58 UTC |
Mehra UneekChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 105,000 | $0.00 Strike: $10.19 | $0.00 |
DisclosureSEC source: 0001193125-26-104384 · ownership.xml · derivative · entry 2 Mehra Uneek · CIK 0001881504 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 105,000 shares Expires 2036-03-09 F2 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:58 UTC |
Mehra UneekChief Financial Officer
|
GrantCommon Stock | 23,330 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-104384 · ownership.xml · nonDerivative · entry 1 Mehra Uneek · CIK 0001881504 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,330 F1 · shares: Represents a grant of restricted stock units ("RSUs"), each representing a contingent right to receive one share of the Issuer's Common Stock. The RSUs vest in 16 equal quarterly installments over a period of four years from January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. The RSUs will be settled in shares of Common Stock upon vesting. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:57 UTC |
Beltran PedroChief Scientific Officer
|
GrantStock Option (Right to Buy) · Derivative | 210,000 | $0.00 Strike: $10.19 | $0.00 |
DisclosureSEC source: 0001193125-26-104379 · ownership.xml · derivative · entry 2 Beltran Pedro · CIK 0002058152 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 210,000 Underlying: Common Stock · 210,000 shares Expires 2036-03-09 F2 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:57 UTC |
Beltran PedroChief Scientific Officer
|
GrantCommon Stock | 46,670 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-104379 · ownership.xml · nonDerivative · entry 1 Beltran Pedro · CIK 0002058152 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,670 F1 · shares: Represents a grant of restricted stock units ("RSUs"), each representing a contingent right to receive one share of the Issuer's Common Stock. The RSUs vest in 16 equal quarterly installments over a period of four years from January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. The RSUs will be settled in shares of Common Stock upon vesting. Read SEC document |
| January 01, 2026 Filed Jan 6, 2026 00:22 UTC |
Wallace Eli M.Director · Chief Executive Officer
|
GrantStock Option (Right to Buy) · Derivative | 1,114,400 | $0.00 Strike: $12.52 | $0.00 |
DisclosureSEC source: 0001193125-26-003027 · ownership.xml · derivative · entry 1 Wallace Eli M. · CIK 0001776352 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,114,400 Underlying: Common Stock · 1,114,400 shares Expires 2035-12-31 F1 · derivative.exercise_date: 69,650 of the shares underlying the option vested on January 2, 2026. Thereafter, 1/48th of the shares underlying the option will vest monthly, with full vesting scheduled for October 2, 2029, subject to the Reporting Person's continuous service with the Issuer on each such vesting date. Read SEC document |
| December 10, 2025 Filed Dec 13, 2025 00:04 UTC |
Wallace Eli M.Director · Chief Executive Officer
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 1,114,400 | Not disclosed Strike: $12.44 | Not disclosed |
DisclosureSEC source: 0001193125-25-317962 · ownership.xml · derivative · entry 1 Wallace Eli M. · CIK 0001776352 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 1,114,400 shares Expires 2035-10-01 F2 · price: On December 10, 2025, the Issuer rescinded 1,114,400 stock options that were part of the Reporting Person's option grant dated October 2, 2025 (the "Rescinded Portion"). The Rescinded Portion was cancelled and the remaining 500,000 stock options from the original grant continue to remain outstanding. The rescission was an exempt disposition to the Issuer per Rule 16b-3. F1 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of October 2, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| October 10, 2025 Filed Oct 16, 2025 17:54 UTC |
BridgeBio Pharma LLC10% owner
BridgeBio Pharma, Inc.10% owner
|
OtherCommon Stock | 784,720 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-25-241634 · ownership.xml · nonDerivative · entry 1 BridgeBio Pharma LLC · CIK 0002076615 · 10% owner BridgeBio Pharma, Inc. · CIK 0001743881 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,589,846 F1 · price: Shares issued pursuant to an amendment to the Transition Services Agreement dated August 11, 2025 in exchange for additional financial and accounting support services provided through December 31, 2025. F2 · ownership.direct: Shares are held by BridgeBio Pharma LLC ("BBIO LLC"). Voting and investment power over the shares held by BBIO LLC is exercised by its parent entity, BridgeBio Pharma, Inc. ("BBIO"). The board of directors of BBIO consists of Neil Kumar, Ph.D., Eric Aguiar, M.D., Jennifer E. Cook, Douglas A. Dachille, Ronald J. Daniels, Andrea J. Ellis, Fred Hassan, Charles Homcy, M.D., Andrew W. Lo, Ph.D., Frank P. McCormick, Ph.D., F.R.S., D.Sc., James C. Momtazee, Ali J. Satvat, Randal W. Scott, Ph.D., and Hannah A. Valantine, M.D. (each a BBIO director, and collectively, the "BBIO Directors"). None of the members of the board of directors of BBIO or BBIO LLC has individual voting or investment power with respect to such shares. Each of BBIO and the BBIO Directors disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Exchange Act, except to the extent of its, his, or her pecuniary interest therein, if any. F3 · ownership.direct: (Continued from Footnote 2) This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| October 02, 2025 Filed Oct 6, 2025 20:22 UTC |
Wallace Eli M.Director · Chief Executive Officer
|
GrantStock Option (Right to Buy) · Derivative | 1,614,400 | $0.00 Strike: $12.44 | $0.00 |
DisclosureSEC source: 0001193125-25-231917 · ownership.xml · derivative · entry 1 Wallace Eli M. · CIK 0001776352 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,614,400 Underlying: Common Stock · 1,614,400 shares Expires 2035-10-01 F1 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of October 2, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| August 26, 2025 Filed Aug 28, 2025 20:37 UTC |
Ben YongChief Med & Dev Officer
|
GrantStock Option (Right to Buy) · Derivative | 357,177 | $0.00 Strike: $9.59 | $0.00 |
DisclosureSEC source: 0000950170-25-111997 · ownership.xml · derivative · entry 1 Ben Yong · CIK 0001967669 · Chief Med & Dev Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 357,177 Underlying: Common Stock · 357,177 shares Expires 2035-08-25 F1 · derivative.exercise_date: A fraction of the shares underlying such option equal to (x) the number of full months between August 11, 2025 ("Vesting Commencement Date") and the date on which a registration statement on Form S-8 is filed and effective with the Securities and Exchange Commission (the "S-8 Filing Date") divided by (y) 48 shall vest on the S-8 Filing Date, and 1/48th of the shares underlying such option shall vest each month thereafter on the day of the month corresponding to the Vesting Commencement Date (and if there is no suchcorresponding day for a month, then the vesting date shall be the last day of the applicable month) until 100% of the shares underlying such option is vested on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous service the Issuer on each such vesting date. Read SEC document |
| August 26, 2025 Filed Aug 28, 2025 20:34 UTC |
Mehra UneekChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 633,570 | $0.00 Strike: $9.59 | $0.00 |
DisclosureSEC source: 0000950170-25-111986 · ownership.xml · derivative · entry 1 Mehra Uneek · CIK 0001881504 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 633,570 Underlying: Common Stock · 633,570 shares Expires 2035-08-25 F1 · derivative.exercise_date: 25% of the shares underlying such option shall vest on July 21, 2026, with the remainder vesting in thirty-six substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service the Issuer on each such vesting date. Read SEC document |
| August 26, 2025 Filed Aug 28, 2025 20:41 UTC |
Bauer JakeDirector
|
GrantStock Option (Right to Buy) · Derivative | 138,193 | $0.00 Strike: $9.59 | $0.00 |
DisclosureSEC source: 0000950170-25-112008 · ownership.xml · derivative · entry 1 Bauer Jake · CIK 0001654909 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,193 Underlying: Common Stock · 138,193 shares Expires 2035-08-25 F1 · derivative.exercise_date: A fraction of the shares underlying such option equal to (x) the number of full months between April 25, 2025 ("Vesting Commencement Date") and the date on which a registration statement on Form S-8 is filed and effective with the Securities and Exchange Commission (the "S-8 Filing Date") divided by (y) 48 shall vest on the S-8 Filing Date, and 1/48th of the shares underlying such option shall vest each month thereafter on the day of the month corresponding to the Vesting Commencement Date (and if there is no suchcorresponding day for a month, then the vesting date shall be the last day of the applicable month) until 100% of the shares underlying such option is vested on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous service the Issuer on each such vesting date. Read SEC document |
| August 26, 2025 Filed Aug 28, 2025 20:44 UTC |
Tipirneni Praveen P.Director
|
GrantStock Option (Right to Buy) · Derivative | 52,269 | $0.00 Strike: $9.59 | $0.00 |
DisclosureSEC source: 0000950170-25-112020 · ownership.xml · derivative · entry 1 Tipirneni Praveen P. · CIK 0001779978 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,269 Underlying: Common Stock · 52,269 shares Expires 2035-08-25 F1 · derivative.exercise_date: A fraction of the shares underlying such option equal to (x) the number of full months between August 11, 2025 ("Vesting Commencement Date") and the date on which a registration statement on Form S-8 is filed and effective with the Securities and Exchange Commission (the "S-8 Filing Date") divided by (y) 48 shall vest on the S-8 Filing Date, and 1/48th of the shares underlying such option shall vest each month thereafter on the day of the month corresponding to the Vesting Commencement Date (and if there is no suchcorresponding day for a month, then the vesting date shall be the last day of the applicable month) until 100% of the shares underlying such option is vested on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous service the Issuer on each such vesting date. Read SEC document |
| August 26, 2025 Filed Aug 28, 2025 20:43 UTC |
MCCORMICK FRANKDirector
|
GrantStock Option (Right to Buy) · Derivative | 91,076 | $0.00 Strike: $9.59 | $0.00 |
DisclosureSEC source: 0000950170-25-112016 · ownership.xml · derivative · entry 1 MCCORMICK FRANK · CIK 0001257809 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,076 Underlying: Common Stock · 91,076 shares Expires 2035-08-25 F1 · derivative.exercise_date: A fraction of the shares underlying such option equal to (x) the number of full months between August 11, 2025 ("Vesting Commencement Date") and the date on which a registration statement on Form S-8 is filed and effective with the Securities and Exchange Commission (the "S-8 Filing Date") divided by (y) 48 shall vest on the S-8 Filing Date, and 1/48th of the shares underlying such option shall vest each month thereafter on the day of the month corresponding to the Vesting Commencement Date (and if there is no suchcorresponding day for a month, then the vesting date shall be the last day of the applicable month) until 100% of the shares underlying such option is vested on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous service the Issuer on each such vesting date. Read SEC document |
| August 26, 2025 Filed Aug 28, 2025 20:39 UTC |
Beltran PedroChief Scientific Officer
|
GrantStock Option (Right to Buy) · Derivative | 357,177 | $0.00 Strike: $9.59 | $0.00 |
DisclosureSEC source: 0000950170-25-112003 · ownership.xml · derivative · entry 1 Beltran Pedro · CIK 0002058152 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 357,177 Underlying: Common Stock · 357,177 shares Expires 2035-08-25 F1 · derivative.exercise_date: A fraction of the shares underlying such option equal to (x) the number of full months between August 11, 2025 ("Vesting Commencement Date") and the date on which a registration statement on Form S-8 is filed and effective with the Securities and Exchange Commission (the "S-8 Filing Date") divided by (y) 48 shall vest on the S-8 Filing Date, and 1/48th of the shares underlying such option shall vest each month thereafter on the day of the month corresponding to the Vesting Commencement Date (and if there is no suchcorresponding day for a month, then the vesting date shall be the last day of the applicable month) until 100% of the shares underlying such option is vested on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous service the Issuer on each such vesting date. Read SEC document |
| August 26, 2025 Filed Aug 28, 2025 20:36 UTC |
Wallace Eli M.Director · Chief Executive Officer
|
GrantStock Option (Right to Buy) · Derivative | 499,731 | $0.00 Strike: $9.59 | $0.00 |
DisclosureSEC source: 0000950170-25-111992 · ownership.xml · derivative · entry 1 Wallace Eli M. · CIK 0001776352 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 499,731 Underlying: Common Stock · 499,731 shares Expires 2035-08-25 F1 · derivative.exercise_date: A fraction of the shares underlying such option equal to (x) the number of full months between August 11, 2025 ("Vesting Commencement Date") and the date on which a registration statement on Form S-8 is filed and effective with the Securities and Exchange Commission (the "S-8 Filing Date") divided by (y) 48 shall vest on the S-8 Filing Date, and 1/48th of the shares underlying such option shall vest each month thereafter on the day of the month corresponding to the Vesting Commencement Date (and if there is no suchcorresponding day for a month, then the vesting date shall be the last day of the applicable month) until 100% of the shares underlying such option is vested on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous service the Issuer on each such vesting date. Read SEC document |
| August 11, 2025 Filed Aug 11, 2025 17:04 UTC |
Holman Albert A IIIFormer Director
|
Exercise / conversionClass B ordinary shares · Derivative | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-074375 · ownership.xml · derivative · entry 2 Holman Albert A III · CIK 0002056154 · Former Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A ordinary shares · 30,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: In connection with and prior to the closing of the business combination between the Issuer (which was formerly known as Helix Acquisition Corp. II, "Helix") and TheRas, Inc., among other things, (i) each of Helix's Class B ordinary shares converted into one Helix Class A ordinary share, on a one-for-one basis, as described under the heading "Description of Securities" in Helix's Registration Statement on Form S-1 (File No. 333-276591), (ii) Helix migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law, as amended, and the Cayman Islands Companies Act (As Revised) (the "Domestication"), and (iii) as a result of the Domestication, each Class A ordinary share of Helix converted into one share of the Issuer's common stock, on a one-for-one basis. Prior to such conversion, the Helix Class B ordinary shares had no expiration date. F1 · kind: In connection with and prior to the closing of the business combination between the Issuer (which was formerly known as Helix Acquisition Corp. II, "Helix") and TheRas, Inc., among other things, (i) each of Helix's Class B ordinary shares converted into one Helix Class A ordinary share, on a one-for-one basis, as described under the heading "Description of Securities" in Helix's Registration Statement on Form S-1 (File No. 333-276591), (ii) Helix migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law, as amended, and the Cayman Islands Companies Act (As Revised) (the "Domestication"), and (iii) as a result of the Domestication, each Class A ordinary share of Helix converted into one share of the Issuer's common stock, on a one-for-one basis. Prior to such conversion, the Helix Class B ordinary shares had no expiration date. F1 · derivative.exercise_date: In connection with and prior to the closing of the business combination between the Issuer (which was formerly known as Helix Acquisition Corp. II, "Helix") and TheRas, Inc., among other things, (i) each of Helix's Class B ordinary shares converted into one Helix Class A ordinary share, on a one-for-one basis, as described under the heading "Description of Securities" in Helix's Registration Statement on Form S-1 (File No. 333-276591), (ii) Helix migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law, as amended, and the Cayman Islands Companies Act (As Revised) (the "Domestication"), and (iii) as a result of the Domestication, each Class A ordinary share of Helix converted into one share of the Issuer's common stock, on a one-for-one basis. Prior to such conversion, the Helix Class B ordinary shares had no expiration date. F1 · derivative.expiration_date: In connection with and prior to the closing of the business combination between the Issuer (which was formerly known as Helix Acquisition Corp. II, "Helix") and TheRas, Inc., among other things, (i) each of Helix's Class B ordinary shares converted into one Helix Class A ordinary share, on a one-for-one basis, as described under the heading "Description of Securities" in Helix's Registration Statement on Form S-1 (File No. 333-276591), (ii) Helix migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law, as amended, and the Cayman Islands Companies Act (As Revised) (the "Domestication"), and (iii) as a result of the Domestication, each Class A ordinary share of Helix converted into one share of the Issuer's common stock, on a one-for-one basis. Prior to such conversion, the Helix Class B ordinary shares had no expiration date. Read SEC document |
| August 11, 2025 Filed Aug 11, 2025 17:04 UTC |
Holman Albert A IIIFormer Director
|
Exercise / conversionCommon Stock | 30,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-25-074375 · ownership.xml · nonDerivative · entry 1 Holman Albert A III · CIK 0002056154 · Former Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: In connection with and prior to the closing of the business combination between the Issuer (which was formerly known as Helix Acquisition Corp. II, "Helix") and TheRas, Inc., among other things, (i) each of Helix's Class B ordinary shares converted into one Helix Class A ordinary share, on a one-for-one basis, as described under the heading "Description of Securities" in Helix's Registration Statement on Form S-1 (File No. 333-276591), (ii) Helix migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law, as amended, and the Cayman Islands Companies Act (As Revised) (the "Domestication"), and (iii) as a result of the Domestication, each Class A ordinary share of Helix converted into one share of the Issuer's common stock, on a one-for-one basis. Prior to such conversion, the Helix Class B ordinary shares had no expiration date. F1 · price: In connection with and prior to the closing of the business combination between the Issuer (which was formerly known as Helix Acquisition Corp. II, "Helix") and TheRas, Inc., among other things, (i) each of Helix's Class B ordinary shares converted into one Helix Class A ordinary share, on a one-for-one basis, as described under the heading "Description of Securities" in Helix's Registration Statement on Form S-1 (File No. 333-276591), (ii) Helix migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law, as amended, and the Cayman Islands Companies Act (As Revised) (the "Domestication"), and (iii) as a result of the Domestication, each Class A ordinary share of Helix converted into one share of the Issuer's common stock, on a one-for-one basis. Prior to such conversion, the Helix Class B ordinary shares had no expiration date. Read SEC document |
| August 11, 2025 Filed Aug 11, 2025 21:01 UTC |
McKenna Mark C.Former Director
|
Exercise / conversionClass B ordinary shares · Derivative | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-074368 · ownership.xml · derivative · entry 2 McKenna Mark C. · CIK 0001749623 · Former Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A ordinary shares · 30,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: In connection with and prior to the closing of the business combination between the Issuer (which was formerly known as Helix Acquisition Corp. II, "Helix") and TheRas, Inc., among other things, (i) each of Helix's Class B ordinary shares converted into one Helix Class A ordinary share, on a one-for-one basis, as described under the heading "Description of Securities" in Helix's Registration Statement on Form S-1 (File No. 333-276591), (ii) Helix migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law, as amended, and the Cayman Islands Companies Act (As Revised) (the "Domestication"), and (iii) as a result of the Domestication, each Class A ordinary share of Helix converted into one share of the Issuer's common stock, on a one-for-one basis. Prior to such conversion, the Helix Class B ordinary shares had no expiration date. F1 · kind: In connection with and prior to the closing of the business combination between the Issuer (which was formerly known as Helix Acquisition Corp. II, "Helix") and TheRas, Inc., among other things, (i) each of Helix's Class B ordinary shares converted into one Helix Class A ordinary share, on a one-for-one basis, as described under the heading "Description of Securities" in Helix's Registration Statement on Form S-1 (File No. 333-276591), (ii) Helix migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law, as amended, and the Cayman Islands Companies Act (As Revised) (the "Domestication"), and (iii) as a result of the Domestication, each Class A ordinary share of Helix converted into one share of the Issuer's common stock, on a one-for-one basis. Prior to such conversion, the Helix Class B ordinary shares had no expiration date. F1 · derivative.exercise_date: In connection with and prior to the closing of the business combination between the Issuer (which was formerly known as Helix Acquisition Corp. II, "Helix") and TheRas, Inc., among other things, (i) each of Helix's Class B ordinary shares converted into one Helix Class A ordinary share, on a one-for-one basis, as described under the heading "Description of Securities" in Helix's Registration Statement on Form S-1 (File No. 333-276591), (ii) Helix migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law, as amended, and the Cayman Islands Companies Act (As Revised) (the "Domestication"), and (iii) as a result of the Domestication, each Class A ordinary share of Helix converted into one share of the Issuer's common stock, on a one-for-one basis. Prior to such conversion, the Helix Class B ordinary shares had no expiration date. F1 · derivative.expiration_date: In connection with and prior to the closing of the business combination between the Issuer (which was formerly known as Helix Acquisition Corp. II, "Helix") and TheRas, Inc., among other things, (i) each of Helix's Class B ordinary shares converted into one Helix Class A ordinary share, on a one-for-one basis, as described under the heading "Description of Securities" in Helix's Registration Statement on Form S-1 (File No. 333-276591), (ii) Helix migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law, as amended, and the Cayman Islands Companies Act (As Revised) (the "Domestication"), and (iii) as a result of the Domestication, each Class A ordinary share of Helix converted into one share of the Issuer's common stock, on a one-for-one basis. Prior to such conversion, the Helix Class B ordinary shares had no expiration date. Read SEC document |
| August 11, 2025 Filed Aug 11, 2025 21:01 UTC |
McKenna Mark C.Former Director
|
Exercise / conversionCommon Stock | 30,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-25-074368 · ownership.xml · nonDerivative · entry 1 McKenna Mark C. · CIK 0001749623 · Former Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: In connection with and prior to the closing of the business combination between the Issuer (which was formerly known as Helix Acquisition Corp. II, "Helix") and TheRas, Inc., among other things, (i) each of Helix's Class B ordinary shares converted into one Helix Class A ordinary share, on a one-for-one basis, as described under the heading "Description of Securities" in Helix's Registration Statement on Form S-1 (File No. 333-276591), (ii) Helix migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law, as amended, and the Cayman Islands Companies Act (As Revised) (the "Domestication"), and (iii) as a result of the Domestication, each Class A ordinary share of Helix converted into one share of the Issuer's common stock, on a one-for-one basis. Prior to such conversion, the Helix Class B ordinary shares had no expiration date. F1 · price: In connection with and prior to the closing of the business combination between the Issuer (which was formerly known as Helix Acquisition Corp. II, "Helix") and TheRas, Inc., among other things, (i) each of Helix's Class B ordinary shares converted into one Helix Class A ordinary share, on a one-for-one basis, as described under the heading "Description of Securities" in Helix's Registration Statement on Form S-1 (File No. 333-276591), (ii) Helix migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law, as amended, and the Cayman Islands Companies Act (As Revised) (the "Domestication"), and (iii) as a result of the Domestication, each Class A ordinary share of Helix converted into one share of the Issuer's common stock, on a one-for-one basis. Prior to such conversion, the Helix Class B ordinary shares had no expiration date. Read SEC document |
| August 11, 2025 Filed Aug 11, 2025 21:00 UTC |
Schmid John P.Former Director
|
Exercise / conversionClass B ordinary shares · Derivative | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-074364 · ownership.xml · derivative · entry 2 Schmid John P. · CIK 0001478916 · Former Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A ordinary shares · 30,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: In connection with and prior to the closing of the business combination between the Issuer (which was formerly known as Helix Acquisition Corp. II, "Helix") and TheRas, Inc., among other things, (i) each of Helix's Class B ordinary shares converted into one Helix Class A ordinary share, on a one-for-one basis, as described under the heading "Description of Securities" in Helix's Registration Statement on Form S-1 (File No. 333-276591), (ii) Helix migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law, as amended, and the Cayman Islands Companies Act (As Revised) (the "Domestication"), and (iii) as a result of the Domestication, each Class A ordinary share of Helix converted into one share of the Issuer's common stock, on a one-for-one basis. Prior to such conversion, the Helix Class B ordinary shares had no expiration date. F1 · kind: In connection with and prior to the closing of the business combination between the Issuer (which was formerly known as Helix Acquisition Corp. II, "Helix") and TheRas, Inc., among other things, (i) each of Helix's Class B ordinary shares converted into one Helix Class A ordinary share, on a one-for-one basis, as described under the heading "Description of Securities" in Helix's Registration Statement on Form S-1 (File No. 333-276591), (ii) Helix migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law, as amended, and the Cayman Islands Companies Act (As Revised) (the "Domestication"), and (iii) as a result of the Domestication, each Class A ordinary share of Helix converted into one share of the Issuer's common stock, on a one-for-one basis. Prior to such conversion, the Helix Class B ordinary shares had no expiration date. F1 · derivative.exercise_date: In connection with and prior to the closing of the business combination between the Issuer (which was formerly known as Helix Acquisition Corp. II, "Helix") and TheRas, Inc., among other things, (i) each of Helix's Class B ordinary shares converted into one Helix Class A ordinary share, on a one-for-one basis, as described under the heading "Description of Securities" in Helix's Registration Statement on Form S-1 (File No. 333-276591), (ii) Helix migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law, as amended, and the Cayman Islands Companies Act (As Revised) (the "Domestication"), and (iii) as a result of the Domestication, each Class A ordinary share of Helix converted into one share of the Issuer's common stock, on a one-for-one basis. Prior to such conversion, the Helix Class B ordinary shares had no expiration date. F1 · derivative.expiration_date: In connection with and prior to the closing of the business combination between the Issuer (which was formerly known as Helix Acquisition Corp. II, "Helix") and TheRas, Inc., among other things, (i) each of Helix's Class B ordinary shares converted into one Helix Class A ordinary share, on a one-for-one basis, as described under the heading "Description of Securities" in Helix's Registration Statement on Form S-1 (File No. 333-276591), (ii) Helix migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law, as amended, and the Cayman Islands Companies Act (As Revised) (the "Domestication"), and (iii) as a result of the Domestication, each Class A ordinary share of Helix converted into one share of the Issuer's common stock, on a one-for-one basis. Prior to such conversion, the Helix Class B ordinary shares had no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.